Rheumatoid arthritis

News in brief: Secukinumab on PBS for nr-axSpA; Cannabis not recommended for chronic pain; MTX action plans

 IL-17A inhibitor reimbursed for nr-axSpa Secukinumab (Cosentyx) has been listed on the PBS for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA). According to manufacturer, Novartis, secukinumab  is the first interleukin-17A (IL-17A) ) inhibitor to be to be reimbursed in Australia for the treatment of active nr-axSpA. The PBS criteria state that to be ...

Already a member?

Login to keep reading.

© 2021 the limbic